SLC5A2 and congenital rubella syndrome: Additionally, the DAPA-CKD trial (NCT03036150), though focusing on dapagliflozin, demonstrated class-level SGLT2 inhibitor efficacy in patients with chronic kidney disease (CKD) and albuminuria, a common CRS precursor.